Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
Effect of Avastin in Juxtafoveal Telangiectasias
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Asociación para Evitar la Ceguera en México
- Registration Number
- NCT00406380
- Locations
- 🇲🇽
Asociacion para Evitar la Ceguera en Mexico, Mexico, DF, Mexico
Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Asociación para Evitar la Ceguera en México
- Registration Number
- NCT00406172
- Locations
- 🇲🇽
APEC, México D.F., Mexico
Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Asociación para Evitar la Ceguera en México
- Registration Number
- NCT00407121
- Locations
- 🇲🇽
Asociacion para Evitar la Ceguera en Mexico, Mexico, Distrito Federal, Mexico
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT00405938
- Locations
- 🇺🇸
Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2016-10-21
- Target Recruit Count
- 13
- Registration Number
- NCT00405405
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
- Conditions
- Interventions
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00403403
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 31
- Registration Number
- NCT00403130
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 11
- Registration Number
- NCT00401817
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT00402883
- Locations
- 🇺🇸
Wellstar Cancer Research, Marietta, Georgia, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 373
- Registration Number
- NCT00399750
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.